Biopharma Wins, Bets, and Scaling
Kilder
- Endpoints: Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
- Endpoints: Mirum notches first Phase 3 victory for its acquired hepatitis delta treatment - Endpoints News
- Endpoints: AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug - Endpoints News
- Endpoints: Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
- Endpoints: Mirum notches first Phase 3 victory for its acquired hepatitis delta treatment - Endpoints News
- Endpoints: AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug - Endpoints News
- Endpoints: Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
- Endpoints: Mirum notches first Phase 3 victory for its acquired hepatitis delta treatment - Endpoints News
- Endpoints: AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug - Endpoints News
- Mugglehead: Summit Therapeutics agrees to US$2B AZN investment - Mugglehead Investment Magazine
- BioPharma Dive: An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
- BioPharma Dive: Breakthrough therapies still need builders
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.